HC Wainwright & Co. Maintains Buy on Arvinas, Lowers Price Target to $90
HC Wainwright & Co. analyst Andrew Fein maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the price target from $135 to $90.
Credit Suisse Maintains Outperform on Arvinas, Lowers Price Target to $78
Credit Suisse analyst Richard Law maintains Arvinas (NASDAQ:ARVN) with a Outperform and lowers the price target from $98 to $78.
7 Analysts Have This to Say About Arvinas
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter:
Jefferies Initiates Coverage On Arvinas with Hold Rating, Announces Price Target of $42
Jefferies analyst Akash Tewari initiates coverage on Arvinas (NASDAQ:ARVN) with a Hold rating and announces Price Target of $42.
Arvinas Says On June 4, Co And Subsidiary Entered Into A Master In Vitro Diagnostics Agreement With Foundation Medicine
Says DealFor Development, Commercialization Of Foundation Medicine's Companion In Vitro Diagnostic Assays For Use With Co's Therapeuti
EPIX: Clinical Update on Phase 1 Monotherapy Trial of EPI-7386 Expected in 2Q22…
By David Bautz, PhD
NASDAQ:EPIX
READ THE FULL EPIX RESEARCH REPORT
Analyst Ratings for Arvinas
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter:
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.